Detalhe da pesquisa
1.
Development of a Unique Rapid Test to Detect Anti-bodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein.
Chimia (Aarau)
; 75(5): 446-452, 2021 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34016243
2.
Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial.
Aging Clin Exp Res
; 32(3): 449-457, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31148099
3.
Role of Biological Markers for Cerebral Bleeding Risk STRATification in Patients with Atrial Fibrillation on Oral Anticoagulants for Primary or Secondary Prevention of Ischemic Stroke (Strat-AF Study): Study Design and Methodology.
Medicina (Kaunas)
; 55(10)2019 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31548494
4.
Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Drugs Aging
; 38(6): 481-491, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855653
5.
4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.
J Med Chem
; 63(22): 13595-13617, 2020 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166139
6.
Association Between Motor and Cognitive Performances in Elderly With Atrial Fibrillation: Strat-AF Study.
Front Neurol
; 11: 571978, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33281708
7.
Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.
ACS Med Chem Lett
; 10(10): 1473-1479, 2019 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31620236
8.
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
J Med Chem
; 62(18): 8609-8630, 2019 09 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31465220
9.
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
J Med Chem
; 62(13): 6241-6261, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31244112
10.
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy.
Neuropharmacology
; 140: 107-120, 2018 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30081001
11.
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
J Med Chem
; 61(22): 10084-10105, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30359003
12.
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.
J Med Chem
; 60(17): 7524-7538, 2017 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28829592
13.
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Nat Commun
; 8: 14683, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28276440
14.
Separation and detection of all phosphoinositide isomers by ESI-MS.
J Pharm Biomed Anal
; 53(3): 552-8, 2010 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20399587